New real-world evidence for Pfizer/BioNTech COVID-19 vaccine
New real-world evidence gathered by the Israel Ministry of Health (MoH) suggests that Pfizer/BioNTech’s COVID-19 vaccine ‘dramatically’ lowers the incidence rates of COVID-19 in fully vaccinated individuals.
The latest analysis from Israel’s MoH found that protection is stronger two weeks after the second dose of the vaccine – effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death.
The findings from the analysis come from de-identified aggregate surveillance data collected between 17 January and 6 March 2021, when the Pfizer/BioNTech vaccine was the only available jab in Israel and when the UK or B.1.1.7 variant was the dominant strain.
The analysis also found vaccine effectiveness of 94% against asymptomatic SARS-CoV-2 infections. Across all outcomes, vaccine effectiveness was measured from two weeks after the second dose.
Read more: http://www.pharmatimes.com/news/new_real-world_evidence_for_pfizerbiontech_covid-19_vaccine_1365128
The latest analysis from Israel’s MoH found that protection is stronger two weeks after the second dose of the vaccine – effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death.
The findings from the analysis come from de-identified aggregate surveillance data collected between 17 January and 6 March 2021, when the Pfizer/BioNTech vaccine was the only available jab in Israel and when the UK or B.1.1.7 variant was the dominant strain.
The analysis also found vaccine effectiveness of 94% against asymptomatic SARS-CoV-2 infections. Across all outcomes, vaccine effectiveness was measured from two weeks after the second dose.
Read more: http://www.pharmatimes.com/news/new_real-world_evidence_for_pfizerbiontech_covid-19_vaccine_1365128
